860508P

C8 Ceramide (d18:1/8:0)

Avanti Polar Lipids 860508P, powder

• Synonyme(s) : N-octanoyl-D-erythro-sphingosine
• Formule empirique (notation de Hill): C₂₆H₅₁NO₃
• Numéro CAS: 74713-59-0
• Poids moléculaire : 425.69
• Code UNSPSC : 12352211
• Nomenclature NACRES : NA.25

Propriétés

• Forme: powder
• Conditionnement: pkg of 1 × 5 mg (860508P-5mg)
• Fabricant/nom de marque: Avanti Polar Lipids 860508P
• Type de lipide: sphingolipids
• Conditions d'expédition: dry ice
• Température de stockage: −20°C
• Chaîne SMILES: OC[C@]([H])(NC(CCCCCCC)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC
• InChI: 1S/C26H51NO3/c1-3-5-7-9-10-11-12-13-14-15-16-18-19-21-25(29)24(23-28)27-26(30)22-20-17-8-6-4-2/h19,21,24-25,28-29H,3-18,20,22-23H2,1-2H3,(H,27,30)/b21-19+/t24-,25+/m0/s1
• Clé InChI: APDLCSPGWPLYEQ-WRBRXSDHSA-N

Description

Description générale

C8 Ceramide is a short chain ceramide and is cell permeable.

Application

C8 Ceramide (d18:1/8:0) has been used as an internal ceramide standard in electrospray ionization. It has also been used as a substrate for ceramide kinase activity assay. It is suitable for use as a substrate for galactocerebrosidase.

Actions biochimiques/physiologiques

C8 Ceramide has anti-tumor functionality. Synthetic liposomal C8 ceramide inhibits hepatocellular carcinoma (HCC). Addition of exogenous C8 ceramide causes necrosis in hepatocytes by decreasing ATP levels and impairing mitochondrial functionality. C8 ceramide inhibition of serine palmitoyl transferase halts de novo sphingolipid biosynthesis. It also acts as chemotherapeutic agent by increasing the reactive oxygen species in lung cancer cells.

Conditionnement

5 mL Amber Glass Screw Cap Vial (860508P-5mg)

Informations légales

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids